Complete Filing Data
Radiopharm Theranostics Ltd reported Cash And Cash Equivalents of $29.12 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Radiopharm Theranostics Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | $3.6M | $299.2K | $292.4K |
| Research And Development Expense | $27.5M | $23.1M | $22.6M |
| Profit Loss From Operating Activities | -$38.2M | -$47.2M | -$34.5M |
| Profit Loss Before Tax | -$38.2M | -$47.9M | -$34.6M |
| Profit Loss | -$38.3M | -$47.9M | -$34.6M |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | $464.0K | $203.0K | -$728.3K |
| Other Comprehensive Income Before Tax | $464.0K | $203.0K | -$728.3K |
| Income Tax Expense Continuing Operations | $103.3K | $96.4K | $38.0K |
| Gross Profit | $39.3K | $299.2K | $292.4K |
| General And Administrative Expense | $14.6M | $13.0M | $12.2M |
| Comprehensive Income Attributable To Owners Of Parent | -$36.2M | -$45.8M | -$35.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | -$1.6M | -$2.0M | -$162.5K |
| Comprehensive Income | -$37.9M | -$47.7M | -$35.3M |
| Research And Development Tax Incentive Received | $4.9M | $1.6M | |
| Cost Of Sales | $3.6M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash And Cash Equivalents | $29.1M | $18.6M | $11.7M | $27.0M |
| Trade And Other Current Receivables | $10.4M | $987.4K | $4.5M | |
| Trade And Other Current Payables | $9.3M | $10.9M | $5.1M | |
| Other Equity Interest | $849.5K | $849.5K | $2.1M | |
| Intangible Assets Other Than Goodwill | $46.6M | $49.1M | $58.5M | |
| Changes In Equity | $53.4M | $29.5M | $18.0M | |
| Cash Flows From Used In Operating Activities | -$36.6M | -$23.0M | -$23.2M | |
| Cash Flows From Used In Investing Activities | $1.8M | -$320.0K | -$1.5M | |
| Cash Flows From Used In Financing Activities | $45.4M | $30.2M | $9.2M | |
| Property Plant And Equipment | $53.5K | $60.8K | ||
| Other Noncurrent Financial Liabilities | $28.7M | $27.1M | ||
| Other Current Financial Liabilities | $3.4M | $6.3M | ||
| Other Current Assets | $337.1K | $288.2K | ||
| Noncurrent Liabilities | $28.7M | $27.1M | ||
| Noncurrent Assets | $46.6M | $49.2M | ||
| Net Assets Liabilities | $42.9M | $27.4M | ||
| Liabilities | $43.6M | $44.7M | ||
| Current Liabilities | $14.9M | $17.6M | ||
| Current Assets | $39.9M | $22.8M | ||
| Assets | $86.5M | $72.0M | ||
| Accumulated Other Comprehensive Income | -$145.7M | -$111.3M | ||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $45.3K | |||
| Other Noncurrent Financial Assets | $40.0K | |||
| Noncurrent Payables | $169.2K | |||
| Issue Of Equity Gross | $3.6M | |||
| Deferred Income Including Contract Liabilities | $1.7M | |||
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | $3.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Proceeds From Issuing Shares | 54.0M | 29.6M | 10.1M |
| Payments To Suppliers For Goods And Services And To And On Behalf Of Employees | $42.8M | $28.1M | $25.2M |
| Payments For Share Issue Costs | $4.7M | $1.5M | $854.8K |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $10.6M | $6.9M | -$15.5M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$14.9K | -$25.0K | $234.6K |
| Payments For License Fee Liabilities | $1.2M | $320.0K | |
| Payments For Intellectual Property | -$3.0M | $1.5M | |
| Payments For Debt Issue Costs | $218.6K | $117.0K | |
| Proceeds From Borrowings Classified As Financing Activities | $7.4M | ||
| Increase Decrease In Shares As Part Of License Acquisition | 3.6M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Diluted Earnings Loss Per Share | $-1.76 | $-12.41 | $-11.32 |
| Basic Earnings Loss Per Share | $-1.76 | $-12.41 | $-11.32 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Receipts From Sales Of Goods And Rendering Of Services | $5.4M | $260.5K | $292.4K |
| Other Income | $10.3M | $1.3M | $6.1M |
| Other Expense By Function | $351.6K | $1.2M | $257.3K |
| Issue Of Convertible Instruments | $2.2M | $3.4M | $4.2M |
| Interest Received Classified As Operating Activities | $800.3K | $50.5K | $145.0K |
| Increase Decrease Through Sharebased Payment Transactions | -$11.3K | $31.7K | $89.1K |
| Gains Losses On Change In Fair Value Of Derivatives | -$4.1M | -$8.9M | -$2.7M |
| Finance Costs | $65.3K | $642.9K | $86.1K |
| Adjustments For Sharebased Payments | $1.9M | $2.6M | $3.0M |
| Repayments Of Current Borrowings | $1.9M | $5.2M | |
| Other Reserves | $13.1M | $37.9M | |
| Options Forfeited | -$221.2K | -$136.5K | |
| Noncontrolling Interests | -$1.9M | -$769.3K | |
| Issued Capital | $176.6M | $100.7M | |
| Increase Decrease Through Transactions With Owners | $51.0M | $8.7M | |
| Current Provisions For Employee Benefits | $450.1K | $399.8K | |
| Shares To Be Issued | 24.2M | ||
| Share Issue Related Cost | $2.6M | ||
| Settlement With Lind | $1.7M | ||
| Issue Of Shares Under The Employee Incentive Scheme | 49.7K | ||
| Issue Of Shares In Lieu Of Services | 103.7K | ||
| Issue Of Shares For Milestone Completion | 741.4K | ||
| Increase Decrease Through Treasury Share Transactions | $900.0K | ||
| Increase Decrease Through Acquisition Of Subsidiary | $1.4M | ||
| Cancellation Of Shares To Be Issued | -300.0K |
Most recent annual filing with the SEC: September 18, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.